MED15

Across TCGA pan-cancer cohorts, MED15 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED15 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MED15 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MED15 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where MED15 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	IV	0.472	0.949	<.001	43	view →
LUAD	DFS	Quartile	All	0.996	0.876	.012	18	view →
PDAC	DFS	Median	II,III,IV	0.675	0.870	.003	13	view →
CCRCC	DFS	Median	III,IV	0.774	0.207	.047	2	view →
LSCC	DFS	Median	All	0.615	0.929	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED15–HNSC (OS)

Open the HNSC breakdown →